Research Papers:

Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response

Melanie J. McCoy _, Chris Hemmings, Chidozie C. Anyaegbu, Stephanie J. Austin, Tracey F. Lee-Pullen, Timothy J. Miller, Max K. Bulsara, Nikolajs Zeps, Anna K. Nowak, Richard A. Lake and Cameron F. Platell

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:19803-19813. https://doi.org/10.18632/oncotarget.15048

Metrics: PDF 2085 views  |   HTML 2255 views  |   ?  


Melanie J. McCoy1,4, Chris Hemmings2,3, Chidozie C. Anyaegbu1, Stephanie J. Austin1,3, Tracey F. Lee-Pullen1,3, Timothy J. Miller1,3, Max K. Bulsara5, Nikolajs Zeps1,3, Anna K. Nowak4,6, Richard A. Lake4, Cameron F. Platell1,3

1Colorectal Research Unit, St John of God Subiaco Hospital, Subiaco, WA, 6008, Australia

2Department of Anatomic Pathology, St John of God Pathology, Wembley, WA, 6014, Australia

3School of Surgery, University of Western Australia, Crawley, WA, 6009, Australia

4School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, 6009, Australia

5Institute for Health Research, University of Notre Dame, Fremantle, WA, 6959, Australia

6Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, 6009, Australia

Correspondence to:

Melanie McCoy, email: [email protected]

Keywords: rectal cancer, regulatory T cells, radiotherapy, chemotherapy, treatment response

Received: September 13, 2016     Accepted: January 07, 2017     Published: February 03, 2017


Neoadjuvant (preoperative) chemoradiotherapy (CRT) decreases the risk of rectal cancer recurrence and reduces tumour volume prior to surgery. However, response to CRT varies considerably between individuals and factors associated with response are poorly understood. Foxp3+ regulatory T cells (Tregs) inhibit anti-tumour immunity and may limit any response to chemotherapy and radiotherapy. We have previously reported that a low density of Tregs in the tumour stroma following neoadjuvant CRT for rectal cancer is associated with improved tumour regression. Here we have examined the association between Treg density in pre-treatment diagnostic biopsy specimens and treatment response, in this same patient cohort. We aimed to determine whether pre-treatment tumour-infiltrating Treg density predicts subsequent response to neoadjuvant CRT. Foxp3+, CD8+ and CD3+ cell densities in biopsy samples from 106 patients were assessed by standard immunohistochemistry (IHC) and evaluated for their association with tumour regression grade and survival. We found no association between the density of any T cell subset pre-treatment and clinical outcome, indicating that tumour-infiltrating Treg density does not predict response to neoadjuvant CRT in rectal cancer. Taken together with the findings of the previous study, these data suggest that in the context of neoadjuvant CRT for rectal cancer, the impact of chemotherapy and/or radiotherapy on anti-tumour immunity may be more important than the state of the pre-existing local immune response.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15048